Tuesday 26 June 2018

26 June 2018 - France-based pharmaceutical synthesis and advanced specialties provider Novacap has agreed to acquire Boston-based pharmaceutical contract development and manufacturing organisation PCI Synthesis to reinforce Novacap's capabilities and offering for the pharmaceutical industry, the company said.
Terms of the transaction were not disclosed.
The combination of the two companies will provide PCI Synthesis with additional resources to continue its development while reinforcing Novacap's leadership in pharmaceutical synthesis with 12 cGMP sites, 2 main R and D centers and its comprehensive range of services and technologies dedicated to clinical development and commercial manufacturing.
The two companies operate complementary CDMO activities and share common values such as entrepreneurship, operational excellence and dedication to customer satisfaction.
Novacap is a global player in pharmaceutical synthesis, advanced specialties and cosmetics.
The Group offers its clients custom manufacturing services for pharmaceutical and specialty markets as well as a large portfolio of APIs and pharmaceutical intermediates.
Novacap posted sales of USD 1bn in 2017, operates 28 industrial plants and employs more than 3,000 people across the world.
PCI Synthesis is a Pharmaceutical Development CDMO and is the largest small molecule drug substance manufacturer in the New England area. PCI Synthesis is also a commercial manufacturer of new chemical entities, generic active pharmaceutical ingredients, and other specialty chemical products for the medical device industry.
BlackArch Partners served as the exclusive financial advisor to PCI Synthesis.